The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Abigail J Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Microbiome, Obesity, Obesity Management. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications used to treat and manage type 2 diabetes mellitus (T2DM) and obesity. The present narrative review explores potential interactions between the gut microbiome and GLP-1 RAs. Limited research has been conducted at the intersection of the gut microbiome and GLP-1 RA therapy. Therefore, this review focuses on potential relationships among GLP-1 RA, the microbiome, body weight, dietary changes, and gastrointestinal symptoms. The review of the current literature reveals significant gaps, particularly concerning the role of diet in mediating or confounding any impact of GLP-1 RA medications on the gut microbiome. Therefore, the body of the review is structured as a series of proposed directional and causal relationships. The limited available evidence suggests changes in behavior, diet, and weight loss resulting from GLP-1 RA treatment are the primary drivers of microbiome changes observed after GLP-1 RA treatment. The review concludes by proposing directions for future studies to clarify the complex interplay between GLP-1 RAs, the gut microbiome, diet, and obesity management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA.
- Riddet Institute, Massey University, Palmerston North, New Zealand.
- Department of Food Science and Nutrition, University of Minnesota, Saint Paul, MN, USA.
- Faculty of Medicine, Thammasat University, Bangkok, Thailand.
- Department of Biology, Macalester College, St. Paul, MN, USA.
- Division of Surgical Outcomes and Precision Medicine, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
ORCID-Profile: Abigail J Johnson
Zitieren
APA
Johnson, A., O'Sullivan, E., Valyasevi, P., Metras, B., Jang, S., Shields-Cutler, R., Hendel, K., Harindhanavudhi, T., & Teigen, L. (2026). The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0219
Vancouver
Johnson A, O'Sullivan E, Valyasevi P, Metras B, Jang S, Shields-Cutler R, et al. The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0219
BibTeX
@article{Johnson2026,
author = {Johnson, Abigail J and O'Sullivan, Erin N and Valyasevi, Peerada and Metras, Breanna and Jang, Subin and Shields-Cutler, Robin and Hendel, Katherine R and Harindhanavudhi, Tasma and Teigen, Levi},
title = {The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0219}
}
EUVIMED